I just wanted to welcome everybody here to our first Grand Rounds for the year. To get started on a really good topic, I just wanted to introduce Dr. August Longino. He completed his MD-MPH at University of Washington School of Medicine and then completed his internal medicine residency at the University of Colorado School of Medicine. He's won a Star Research Award for SCM and has done some international research as well and obviously had local grants.
other awards as well. So just wanted to introduce them today. We are definitely excited to have you talk about a very, very important topic. I think every time I talk to my trainees, we talk about how fluid and volume status is the holy grail of critical care in many ways. And if anyone can decipher some of that, they would make a million dollars or more. And so I think VEX's here is super, super, super important. We talk about what does it mean to be found responsive or congested. And so really excited to hear your talk today. And thank you for coming. Thanks for having me. My name is August Longino. As he said, I just graduated from the University of Colorado.
And I'm here today to talk about something near and dear to my heart, and those of my patients, which is venous excess ultrasound, or VEXIS. So today, my hope is that we will get to talk about a couple different things. First of all, what is venous excess ultrasound, and why do we need it? I want to talk about the evidence that supports your use of VEXIS with your patients. And then also, what holes still exist in that evidence, and what are questions that still need answering, and how we might be able to work together to answer those questions. So, as you guys probably all know, there's an ironclad law of nature, which is that every talk like this one has to start with a case. So here's ours.
So you come down out of the ICU, you're in the emergency department, and you've seen your patient, you're on your way back up the stairs when someone grabs you by the arm and says, hey, quick curbside, do you mind just stopping in room three? I want you to lay eyes on this guy. You say, sure. Go in, you see a 67-year-old rancher. He's got a history of colon cancer, and he's coming in with some shortness of breath and some leg swelling. He tells you that he's supposed to take some silly water pill, but he doesn't take it because he doesn't need them. And his kids are there, and they say that dad struggles to use his pills and stick to his diet, especially when he's stressed out.
So you look over at the monitor, and you see that he's pretty tachycardic. He's kind of tachypneic. He's starting to desat. You're talking to him. They're wheeling the BiPAP into the room. And his blood pressure is low and dropping. He's got crackles in his lungs. You try to do a good volume assessment, but he's just got one of those necks, you know? It's hard. You get his legs. They're warm. He's got some edema down there below his shins. And you go back to the computer, and you see some red numbers. So he's got a little AKI. He's got some hyperkalemia. CBC looks OK. His BNP is up. His trope is down. And his lactate is 2.4. His EKG just shows some LBH.
And here's his chest x-ray. We'll pause here for a moment. Everyone can squint. The radiologist encourages you to correlate clinically. So you do that. You put the pieces together. And you're down there in the ED. You start to order some curosamide when all of a sudden this alert flashes on your screen and says the lactate is 2.4. This man has sepsis. Immediately give him a 30 cc per kilogram bolus. So you think to yourself, what is this man's volume status? And how do I know? Well, here I'd like to actually pause. And in addition to asking how do we know, ask why do we care? And it turns out that in our patients with heart failure, as you might know, decongestion is absolutely critical.
I really like this figure, which is a central illustration from a paper by Rubio Garcia and colleagues. It came out in 2018. It was a subgroup analysis of the dose trial. What they did was they looked at patients one week after discharge following a hospitalization for acute decompensated heart failure. And if you were congested at one week, you had a much higher likelihood of dying in the months and years following your hospitalization and also a much higher rate of heart failure re-hospitalization. And because of studies like these, the most recent AHA guidelines recommend that we squeeze these patients completely dry before we let them go home. We want to achieve complete decongestion.
Now, you and I both know that this is easier said than done because volume status is vexing. After all, what is volume status? I found in my brief career as an internal medicine resident and attending that if you take three doctors and you put them in a room with a patient and you ask them, what is the patient's volume status? You are likely to get at least four different answers. And that's because everyone looks at something else to tell them about volume status. Some people look at weight change. Some people look at urine output. Some people look at edema. Others at JVP. What the literature agrees on is that the inter-rater reliability of any of these parameters is extremely poor. And that the likelihood that two doctors are going to tell you that a patient has the same volume status is lousy.
I would argue that when we ask about volume status, we're actually trying to ask about two questions that are a little bit less nebulous. The first of these is fluid responsiveness. Would my patient benefit from extra fluid? We're all very familiar with this concept. This is the paradigm that we all use for sepsis resuscitation. I think a more germane question to the current topic is whether or not fluid is hurting my patient. We call this fluid tolerance. And this concept, I think, is a little bit less accessible than that of fluid responsiveness.
So how can fluid hurt my patient? I would argue that we sometimes struggle with this question because historically we've really focused on the arterial side of the circulation, right? If someone tells you, hey, this patient is unstable, this patient is crashing, the first number that you look at when you go into the room is probably going to be the systolic blood pressure or maybe the MAP. I'm here today to tell you that we should actually be caring about a different parameter, which is the organ perfusion pressure. And the organ perfusion pressure actually represents a gradient. So this is the difference between the mean arterial pressure, the MAP, and the mean systemic filling pressure. That is to say, the venous pressure that your arterial circulation has to overcome in order to carry oxygen to your tissues and carry CO2 away.
As you can see from this handy-dandy cartoon, you can get hypoperfusion by having a low MAP or a high PMSF. I think an illustrative example here is cardiorenal syndrome. It was for me. So when I was a medical student, I was taught about cardiorenal syndrome by a cardiologist who told me that cardiorenal syndrome happens because the heart is sick and it cannot pump blood to the kidneys, which makes the kidneys upset. Not that long ago, a group of nephrologists actually set out to sort of flesh out that concept a little bit more. And they were interested in the relationship between creatinine, ejection fraction, cardiac output, and central venous pressure. Basically, in answering the question, does AKI result from a problem with forward flow or congestion? And so they got about 180 patients that were getting right heart caths and BNPs to answer that question.
And this is what they found. So this is one of the central pictures from their manuscript. And here you have GFR on the y-axis, and then tertiles of ejection fraction on the x. And here you can see that those columns are all about the same height. But interestingly, when you look at central venous pressure, a measure of intracardiac pressures, you do see a relationship. That upper tertile of CDP has a much lower GFR than the lowest tertile. That's what they found when they did the math. No relationship with ejection fraction, significant relationship with CDP. That led them to publish this great little manuscript in clinical cardiology back in 2011, showing that cardiorealike AI was associated with increased cardiac filling pressures, but not low cardiac output.
These are some representative quotes from their discussion and conclusion, basically showing that serum creatinine was correlated with invasively measured CDP, but not CI or CO, and then serum creatinine correlated with the velocity of tricuspid regurgitation, but not with ejection fraction. That's because cardiorene-like AI is not due to hypotension, but rather a deranged perfusion pressure, much to the surprise of my cardiologist mentor. Now, I hear you saying, that's one study back in 2011, 180 patients. What's that to me? But I'd like to point out that this is something that we've known for a long time. This is a citation from the Journal of Physiology, one of the earliest physiology journals we have. About 100 years ago, in 1931, Fred Winton was doing absolutely terrible, cruel things to dogs. And he found out that it was the venous pressure on the kidney, not the arterial pressure, that had the greatest impact on urinary flow or urinary output. So I hope that at this point, I've convinced you that, first of all, venous congestion is real and that it matters to our patients. And it's something that we should care about. And if we care about it, we should be able to measure it.
So how would we go about doing that? Well, we've got a lot of options. We can do a right heart cath, we can do a physical exam, or in the modern era, we can use an ultrasound. We'll start with a right heart cath. This is our gold standard. I think that most of us would agree that if you have a right atrial pressure over 10 millimeters of mercury, you're congested. And the pros of this option are, of course, that this is the definitive measurement. This is the gold standard. When you really want to know what your patient's volume status is, you've got to drop a SWAN. There are some cons. This is resource intensive. In order to do this, you need a cath lab, you need a cardiologist, although some more senior pulmonologists will, of course, argue that they can still flow to SWAN by God. But in the modern era, I think less so.
This is an invasive procedure, so there are risks associated with accessing people's central masculature, and it's time-consuming. It's really hard to do a cath, do something, and then see how your patient responds. So a precise but imperfect measure. We need something new. So what we need is something that is cheap, it's non-invasive, it's repeatable under dynamic conditions, it's reliably reproducible, and it's accurate. So I've always been jealous of cardiologists because they have a perfect test. The cardiologists have the ECG, which satisfies all of these conditions, and what I want is an ECG for venous congestion.
Enter venous excess ultrasound. So back in 2020, Philippe Rolla, Rory Spiegel, and a bunch of other folks up in Canada developed this technique. What is it? It's a four-point ultrasound exam. It involves IVC measurement and then Doppler ultrasound of the hepatic portal and renal veins. And it is billed as a non-invasive means of determining your level of venous congestion.
This was what has now become really a landmark article back in 2020 in the Ultrasound Journal, in which what they did was 706 serial exams of 145 post-cardiac surgery patients. And they did some really innovative modeling in order to figure out what is the exact constellation of Doppler waveform findings and locations that best predicts post-op AKI in these patients, cardiorenal AKI and post-cardiac surgery folks. And so they derived the VEXIS score, venous excess ultrasound score. And they found that a VEXIS grade of three had a positive likelihood ratio of 6.4 for post-operative AKI, which was better than central venous pressure measurements, better than invasive measurement. And so in their discussion conclusion, they said, hey, guys, this is fast, safe, and it might be better than right hard cast. Pretty amazing. So having heard this, you're probably clamoring to know how to do it. Many of you may already know.
But just to summarize, this is a complicated slide. I'm not going to walk all the way through it. So teaching VEXIS is a different talk. But what I want you to take away is that there's a Doppler ultrasonographic measurement of the hepatic vein, the portal vein, and the renal vasculature. And then each of those can be split into one of three conditions. You're either normal, mildly congested, or severely congested. So you end up with this three-by-three matrix that you can then use to interpret your overall VEXIS grade, which ranges from a grade of zero to a grade of three, with zero being small, small IVC, nothing to worry about, move on, all the way up to severe congestion with a big IVC and at least two severely abnormal waveforms.
Remember, it was that Vexus grade of three that was associated with post-operative AKI. So this was the prevailing attitude when this paper first came out, and I tended to agree with it because there's lots of reasons to be skeptical of this, right? There's very few. At that time, there were no prospective validation studies. There was no comparison to our current gold standard of Breit-Heart-Caft. Plus, what about replicability? Just because these experts up in Canada can get this done, that doesn't mean that I can do it or my residents can do it. What about feasibility? How long does it take to acquire all those views and interpret them on the fly?
What about generalizability? It's all well and good to do this in 105 post-cardiac surgery patients, but those aren't necessarily the patients that I'm caring for. We should keep looking at MEX. So I wanted to do a validation study. I had some time. I had a research year. And so I wanted to ask the question, basically, how does VEXIS line up with right heart cath data? So what is the relationship between your VEXIS grade, your intracardiac pressures? And then we also looked at biomarkers and then the patient-centered outcomes of AKI and diuresis. What we did was that every patient who came through our center and was getting a right heart cath, we'd grab them right before their cath and we would offer them a VEXIS exam.
Most of them said yes. Now, who were these patients? I won't make you go through the whole table one here, but I'll say that they were mostly Ward's level heart failure. There's a little bit of a skew to this population because patients had to be able to provide informed consent. And so we're not talking about a lot of the patients that you guys see every day in the ICU. The image interpreters and ultrasonographers were blinded from the right heart catheter that was generated by the interventional cardiologist. And as you can see on the right, we screened 100 people. We ultimately did scans on 91 of them. And then about 10 people got kicked out either because their images were too poor to consider or because their cases got canceled after their VEXA score. So we ended up with about 80 people.
This is what we found. So on the left of the screen, you'll see something that looks a lot like a Georgia O'Keeffe painting. This is a violin plot. For those of you who haven't seen violin plots in the past, it basically works like a box plot, and those horizontal lines are quartiles. But the shape of the column represents the distribution of the data. And so I think it's a little bit more evocative than just a box plot. These red lines that you see represent on the y-axis a right atrial pressure of 10 and 7. And what you can see here is that patients who had a vexous grade of 3 all had a right atrial pressure that was over 10, as did the majority of patients who had a vexous grade of 2.
And then those with a Vexus grade of 0 or 1 had about the same distribution, low or normal, right atrial pressures. In addition to this categorical assessment, we did some math. And so this is our linear correlation after we controlled for age, sex, and Charleston comorbidity index. And we found that there was a very significant relationship between Vexus and right atrial pressure with a pretty steep beta, pretty steep slope. We wanted to dichotomize this and make it clinically useful. So it's all well and good to know that, yeah, sure, there's a relationship between some things, but how do you actually apply it? So we went on to dichotomize patients into dry patients and wet patients. So patients who had a right atrial pressure of less than seven, we called dry. And we said, how good is Vexis at detecting dry patients? And what we found is that on the receiver, the ROC curve that we created, Vexis had an area under the curve of 0.79, 79%, which was not that much better than IVC diameter or IVC collapsibility index, the other tools that we frequently use to try to answer this question. And the confidence intervals overlapped pretty widely.
So if you want to find a dry patient, someone with a lower atrial pressure, Vexus is just as good as anything else we do. However, if you're looking for patients who are congested, who have a right atrial pressure of 10 or more, Vexus actually had a really good area under the curve. So it had an area under the curve of 90% with non-overlapping confidence intervals with IVC diameter and IVC collapsibility. So what I took away from this analysis was that if I want to see if my patient is wet or not, if they have volume to give, then the Vexus is the right tool. We also looked at pulmonary capillary wedge pressure. So we also wanted to look at the left side of the heart. We found a similar relationship where patients with a VEXIS grade of two or three had significantly elevated pulmonary capillary wedge pressures, whereas it's zero and one were in the normal range. After controlling for those same factors, we saw that that linear relationship held true. And that was, you know, that for us was kind of, that was the meat of the study. We were really excited to find that VEXIS accurately represents and basically measured chemodynamics. But then we wanted to learn about some patient-centered outcomes.
So a big question that comes up for our hospitalized heart failure patients is how much can I diurese this person? Is there any way to predict how long they'll be in the hospital or how much they have to give? What this analysis was, was we looked at the relationship between the Vexus grade at the time of your right heart catheterization and then how much weight you lost between the time of right heart cath and discharge. With the assumption being that weight that you lost in the hospital was probably due to diuresis. This is a subgroup analysis of patients who were coming in with acute decompensated heart failure undergoing IV diuresis.
And what we found, as you can see here, is that patients who had a vexis grade of three on the right side of the graph, the time of their right heart catheterization, had the greatest negative change in weight between the time of cath and the time of discharge, which we took to mean that these patients have the greatest diuretic potential. Someone has a high vexis, you can diaries the heck out of them. This was also a significant finding with a pretty solid slope. Most excitingly, perhaps, we looked at acute kidney injury. So we went back and said, OK, who got AKIs? What was that associated with? And we found that AKI was associated first with vexis grade.
as well as right atrial pressure and pulmonary capillary wedge pressure. But there was no significant association between AKI and cardiac output or index. If that sounds familiar, it's because that's exactly what Nanaras and Googling showed us at the top of this talk. So once again, we're sort of recapitulating this idea that venous congestion is actually really important for our patients, especially when it comes to AKI. So what did we find? So this was our first big paper that we published in CHEST. And what we found was that VEXUS is associated with things that we should care about, right atrial pressure, wedge pressure, diuretic potential, AKI, all things that we care about for our patients.
We zoom out and think about practical applications. Who could we use this for? I think there's a lot of options. You know, could you guide diuresis in your heart failure patients or your cirrhotic patients? Could you guide fluid resuscitation in sepsis or septic shock? This is a population that I care a lot about. I'm very interested in this idea of fluid tolerance versus responsiveness. I think right now we exist in this world where we do the passive leg raise and the machine tells us, oh, your patient is volume responsive. And we have kind of a volume responsiveness Lasix reflex, where we give fluid as soon as we see someone is volume responsive. We sort of have a gas pedal for fluids right now in volume responsiveness. I don't think that we have a good brake pedal. And our patients are still at risk of over-resuscitation. So I often wonder if something like VEXIS, a measure of venous capacitance, could act as a brake pedal to avoid over-resuscitation in our sepsis population.
Other things that people have posited is could you use VEXIS or some close relative of VEXIS to look at ECMO weaning or pulmonary hypertension screening? I think if we all sat around for 10 minutes, you know, we could come up with a lot of different potential uses for an ECG for venous congestion. Can I ask you a quick question? Of course. So my understanding, and I'm not an ultrasound expert, but my understanding is that cirrhosis can like alter your IVC variability. So I was wondering if you excluded those patients in your study or if we know that we can use it in that population. Great question. You should answer that question. And then my other question was, did you use intubated patients or were these patients going to the cath lab all with their natural airway? Can I have one slide? Yeah, of course. You can have 10 slides. What's next? Much remains unknown.
So first of all, what about inter-user variability? An important question whenever we're looking at a new ultrasound technique, these tend to be very user-dependent. And then what about unexplored patient subpopulations? So there are patients that you could reasonably think would have all sorts of confounders to this exam. Patients with tricuspid regurgitation, patients with portal hypertension or cirrhosis, patients with end-stage renal disease, what do their kidneys even look like on Doppler? And of course, positive pressure ventilation. Also, what about dynamic changes to fluid status? After all, we only looked at a single point in time. Do we know that if I change something in my patient, is their VEXA score also going to change? All these questions still need to be answered.
And we started. So I want to share with you some data looking at some of these questions. So the first of these was looking at inter-rater reliability and inter-user reproducibility. What we did for this study was we got 84 sets of VEXIS images. And importantly, about 60 of them had an ECG tracing. And then each exam, we got to be interpreted by a variety of different attendings, cardiology, an intensivist, an emergency medicine doc, and a hospitalist. The question we were asking was, with this novel technique, can a bunch of experts look at the same set of images and come to the same conclusion?
And we found that the answer was overall, yes. There was a pretty high cap of statistic for VEXIS alone, but it got even better when you add an ECG tracing. The next question that we've started to ask is looking at those subpopulations. So in answer to your question, doctor, we did not exclude cirrhotic patients with the specific intent of later doing subgroup analyses to try to see if these relationships held true. So the first example of this is that we have looked at patients with tricuspid regurgitation, of course, have kind of deranged hepatic vein waveforms. And we looked at 36 patients with TR, and we found that the relationship persisted.
Regardless of whether you had mild, moderate, or severe tricuspid regurgitation, we still see that linear association between VEXIS and red atrial pressure. I'll pause here to answer your question. We right now do not have enough cirrhotic patients in our population to run a reasonable subgroup analysis, but we would be really excited if you wanted to help us do a similar study and try to figure out what does VEXIS look like in the cirrhotic population. And similarly, positive pressure ventilation, people with GIST or intra-abdominal tumors, there are a lot of populations that we need to figure out what VEXIS or what Doppler ultrasound looks like in them. We also looked at dynamic changes. So this is a great study that was done by Katerina Leyva, who's here today, one of our residents who's invested in this work. So she looked at a bunch of end-stage renal disease patients, and they got paired VEXIS scans before and after hemodialysis. And we saw that there was a clear and significant decrease in your VEXIS score after you got hemodialysis that correlated with a change in the number of B lines that we saw on your lung focus.
And this is, I think, some of the most exciting work we're doing right now. So we are interested in looking at sort of novel scoring systems. One of the things that Vexus does is it's easy, it's intuitive, but it's a little bit of a blunt instrument where it only has, you know, zero through three gradations. And we're leaving, I think, some nuance on the table. This is a study that was done by another one of our residents, Dr. Nabrisky. And he basically camped out in our cardiac ICU for about a month. And everyone who came in with acute decompensated heart failure got a Vexus scan on every day of their admission. We tried to hit them on their day of discharge as well.
And what we saw was that while Vexus did not correlate perfectly with your hospital day, we developed a new score called a congestion score, which basically takes into account more nuance within those Doppler waveforms and allows a grading scale of 0 to 10 instead of 0 to 3. And when we added that nuance, we could see that there's actually a really nice decrease. We saw a very clear relationship between diuretic volume or diurese volume in hospital day and your congestion score. So this tells me that there's a lot more to learn about how we can use Doppler ultrasound to figure out what's happening in our patient circulation. And as I said, we have negative linear associations with total and daily fluid balance based on this congestion score. It's very exciting for us. We've been able to do all this work with very minimal funding, very minimal institutional support, basically because of a large multidisciplinary volunteer team. So we have support from the pulmonary and critical care department through Dr. Ivor Douglas, Matt Resinti in the emergency department, and a few of the cardiology attendings at our program. They provide a lot of oversight and mentorship. But the folks that are really doing the work are mostly residents, fellows, APPs, and medical students, all of whom really donate their time to let us gather this data and generate these results.
There's, of course, more to do. So there's always more subpopulations. I would love to look at this in cirrhosis. I would love to look at this in transplant patients. I think that there's, you know, if we sort of step back, there's a lot we can learn about a lot of different sets of patients using Doppler ultrasound. Right now, we are conducting a prospective study of Vexus and heart failure to look at its prognostic capability for predicting AKI with diuresis, as well as predicting likelihood of readmission. Also, a prospective study of Vexus and sepsis, answering that earlier question that I posited about whether or not you can use Vexus to see when a patient's tank is full and when we can stop fluid resuscitating them before we give them pulmonary edema.
Currently at Baylor, they're looking at Vexis for an ECMO weaning protocol. And as I mentioned, we're very interested in new Doppler-based protocols for different causes and different patient populations. And there's a lot of potential for multi-site collaboration here, as I alluded to. So right now, we are becoming the central IRB for a multi-site study between Baylor, as well as NYU and MGH, to answer some of these outstanding questions. I would love to have any and all of you join us in that endeavor. If this topic is of interest to you, please come join us. Learn VEXIS from experienced mentors and teachers, connect with senior levels of our leadership. And if you have an idea, if this is sparked curiosity in you, we would be happy to share data and collaborate on ways to answer those questions. I'd like to thank my senior mentors, Dr. Ivor Douglas, Dr. Gill, Dr. Burke, Dr. Vicente, and of course, the inventors of the original VEXIS score, Dr. Spiegel, Rola, Bobin, Soligny, et al.
and all the many co-scanners and co-authors who have helped me generate this data and generate these publications, Dr. Martin, Dr. Leyva, Dr. Siegel, and many, many more, as you saw, to Dr. Levine in absentia for this kind invitation, and to all of you for your time and attention today.